-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
Pfizer today announced that it has initiated a Phase 2/3 clinical trial of Paxlovid, an oral antiviral drug for COVID-19, in children aged 6 to 17
Paxlovid was previously authorized by the U.
More than 11 million children under the age of 18 have tested positive for COVID-19 in the U.
The Phase 2/3 clinical trial conducted by Pfizer will include approximately 140 patients and will be divided into two groups for evaluation to determine the effect of different doses of treatment at different body weights
Pfizer said clinical trials in patients 18 and older showed that Paxlovid reduced the risk of hospitalization or death by 89 percent if patients were able to take Paxlovid within a few days of their first symptoms
It is worth noting that the drug has also achieved market breakthroughs in mainland China, where Paxlovid just received conditional approval from mainland Chinese regulators in February this year
In addition to Pfizer's Paxlovid, Merck's oral antiviral drug Molnupiravir for outpatients has also been successfully launched
Reference source:
1.
2.
3.
